Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W E P Beyer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Vaccine|June 29, 2017
Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trialsW E P Beyer, A M Palache, M Boulfich, et al.
Virus Research|May 28, 2004
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?W E P Beyer, A M Palache, G Lüchters, et al.
Vaccine|January 31, 2002
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysisW E P Beyer, A M Palache, J C de Jong, et al.
Vaccine|June 1, 2011
Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysisW E P Beyer, J J P Nauta, A M Palache, et al.
Vaccine|November 3, 2009
Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002A C G Voordouw, W E P Beyer, D J Smith, et al.
Developments in Biologicals|April 20, 2004
Haemagglutination-inhibiting antibody to influenza virusJ C de Jong, A M Palache, W E P Beyer, et al.
Annals of the Rheumatic Diseases|October 30, 2007
The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccinationL B S Gelinck, A E van der Bijl, W E P Beyer, et al.
Science (New York, N.Y.)|November 22, 2014
Antibody landscapes after influenza virus infection or vaccinationJ M Fonville, S H Wilks, S L James, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Vaccine|June 29, 2017
Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trialsW E P Beyer, A M Palache, M Boulfich, et al.
Virus Research|May 28, 2004
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?W E P Beyer, A M Palache, G Lüchters, et al.
Vaccine|January 31, 2002
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysisW E P Beyer, A M Palache, J C de Jong, et al.
Vaccine|June 1, 2011
Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysisW E P Beyer, J J P Nauta, A M Palache, et al.
Vaccine|November 3, 2009
Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002A C G Voordouw, W E P Beyer, D J Smith, et al.
Developments in Biologicals|April 20, 2004
Haemagglutination-inhibiting antibody to influenza virusJ C de Jong, A M Palache, W E P Beyer, et al.
Annals of the Rheumatic Diseases|October 30, 2007
The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccinationL B S Gelinck, A E van der Bijl, W E P Beyer, et al.
Science (New York, N.Y.)|November 22, 2014
Antibody landscapes after influenza virus infection or vaccinationJ M Fonville, S H Wilks, S L James, et al.
Pageof 1